Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001733072 | SCV001983221 | uncertain significance | not provided | 2021-10-05 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV002496061 | SCV002787349 | likely benign | Polycystic kidney disease, adult type | 2024-03-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003247005 | SCV003940909 | uncertain significance | Inborn genetic diseases | 2023-04-26 | criteria provided, single submitter | clinical testing | The c.5746G>C (p.A1916P) alteration is located in exon 15 (coding exon 15) of the PKD1 gene. This alteration results from a G to C substitution at nucleotide position 5746, causing the alanine (A) at amino acid position 1916 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004741059 | SCV005359161 | uncertain significance | PKD1-related disorder | 2024-05-01 | no assertion criteria provided | clinical testing | The PKD1 c.5746G>C variant is predicted to result in the amino acid substitution p.Ala1916Pro. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0057% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |